Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/soligenix-announces-pricing-of-4-75-million-public-offering-302120465.html
https://www.prnewswire.com/news-releases/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure-prophylaxis-against-marburg-marburgvirus-infection-302115205.html
https://www.prnewswire.com/news-releases/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure-prophylaxis-against-sudan-ebolavirus-infection-302113685.html
https://www.biospace.com/article/releases/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure-prophylaxis-against-sudan-ebolavirus-infection/
https://www.prnewswire.com/news-releases/soligenix-announces-recent-accomplishments-and-year-end-2023-financial-results-302090005.html
https://www.prnewswire.com/news-releases/soligenix-announces-formation-of-behcets-disease-medical-advisory-board-302057074.html
https://www.prnewswire.com/news-releases/soligenix-to-present-at-the-microcap-conference-302043250.html
https://ir.soligenix.com/2024-01-08-FDA-Grants-Soligenix-Fast-Track-Designation-for-Dusquetide-in-the-Treatment-of-Oral-Lesions-of-Behcets-Disease
https://www.prnewswire.com/news-releases/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-302025994.html
https://www.prnewswire.com/news-releases/soligenix-announces-publication-demonstrating-complete-protection-against-filovirus-disease-in-nonhuman-primate-models-of-ebola-and-marburg-viruses-302024103.html